Rapid Expansion Of Peptide And Nanobody Drug Conjugates

Peptide and nanobody drug conjugates are moving from specialized research concepts to a more visible segment of the global development pipeline. A Citeline analysis presented at PEGS 2026 identified 106 active programs worldwide, with many still in early development but an increasingly meaningful number advancing toward approval. The findings point to a category gaining momentum across oncology and other therapeutic areas, supported by the targeting potential of peptides and nanobodies and the growing interest in more precise drug delivery approaches. Alongside approved products, several late-stage candidates are expected to reach regulators within the year, making this an important space to watch for shifts in clinical strategy, competitive positioning, and future market opportunity.

Access the full white paper for a clearer view of where the pipeline is headed.